MindBio Therapeutics (MBIO)

PRESS RELEASE

published on 03/20/2024 at 09:50, 1 year 2 months ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression

MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
PRESS RELEASE

published on 03/20/2024 at 09:50, 1 year 2 months ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results

Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRIEF

published on 03/04/2024 at 11:05, 1 year 2 months ago

MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur

MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRIEF

published on 03/04/2024 at 11:05, 1 year 2 months ago

MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder

Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
PRESS RELEASE

published on 03/04/2024 at 11:00, 1 year 2 months ago

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp

Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRIEF

published on 02/26/2024 at 10:30, 1 year 3 months ago

MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression

Depression MB22001 Essai Clinique MindBio Microdosage
BRIEF

published on 02/26/2024 at 10:30, 1 year 3 months ago

MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression

Depression MB22001 MindBio Microdosing Clinical Test
PRESS RELEASE

published on 02/26/2024 at 10:30, 1 year 3 months ago

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks

Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
PRESS RELEASE

published on 02/14/2024 at 10:00, 1 year 3 months ago

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development

MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
PRESS RELEASE

published on 01/30/2024 at 08:10, 1 year 4 months ago

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions

MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD

Published on 05/31/2025 at 06:16, 19 hours 37 minutes ago

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Published on 05/31/2025 at 03:30, 22 hours 23 minutes ago

Avant Brands Inc. Announces Voting Results From 2025 Annual General Meeting of Shareholders
Published on 05/31/2025 at 01:45, 1 day ago

GLG Life Tech Corporation Reports 2025 First Quarter Financial Results
Published on 05/30/2025 at 23:10, 1 day 2 hours ago

CORRECTION: Nextech3D.ai Migrates MAP Dynamics to AWS, Enabling Scalable AI Architecture and Accelerated Deployment
Published on 05/30/2025 at 23:00, 1 day 2 hours ago

Battery X Metals Achieves Full Capacity Recovery on a Real-World Imbalanced Battery from the #2 Out-of-Warranty Electric Vehicle Model in the United States in Preliminary Trial

View all ACCESSWIRE

Published on 05/31/2025 at 21:00, 4 hours 53 minutes ago

Leclanché annonce le dépôt d'une demande de prolongation du délai de publication du rapport annuel 2024 et la suspension temporaire de la cotation de ses actions nominatives à la SIX Swiss Exchange
Published on 05/31/2025 at 21:00, 4 hours 53 minutes ago

Leclanché SA: Leclanché announces filing of request to extend the publication deadline for the 2024 Annual Report and the temporary suspension of trading of its registered shares on SIX Swiss Exchange
Published on 05/31/2025 at 18:37, 7 hours 15 minutes ago

Meyer Burger files for insolvency for German subsidiaries
Published on 05/31/2025 at 14:50, 11 hours 2 minutes ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/31/2025 at 14:46, 11 hours 6 minutes ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets

View all EQS

Published on 05/30/2025 at 22:00, 1 day 3 hours ago

Information sur les comptes annuels
Published on 05/30/2025 at 22:00, 1 day 3 hours ago

Information on the Annual Financial Statements
Published on 05/30/2025 at 18:14, 1 day 7 hours ago

Emova Group - Rapport annuel de Durabilité 23/24
Published on 05/28/2025 at 23:00, 3 days 2 hours ago

Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 3 days 2 hours ago

Engagements collectifs de conservation de titres de la société

View all LES ECHOS COMFI WIRE

News